Alpha-1-Antitrypsin Mediator for GvHD Mitigation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating bone marrow transplantation complications, such as graft versus host disease (GvHD) and rejection, are inadequate, leading to significant morbidity and mortality, and existing immunosuppressive therapies have toxic side effects and imperfect efficacy.
Innovation Solution
Administration of alpha-1-antitrypsin (AAT) or its carboxyterminal derivatives before, during, or after bone marrow transplantation to reduce serine protease activity, thereby mitigating GvHD and improving graft survival by modulating the immune response and reducing pro-inflammatory cytokines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive therapies are used to treat graft versus host disease and rejection, then graft survival is improved, but toxic side effects and imperfect efficacy occur
Solution Approach 1:
The patent uses alpha-1-antitrypsin as an intermediary substance that mediates protection against serine protease-mediated damage in GvHD. Instead of directly suppressing the immune system with toxic drugs, AAT acts as a protective mediator that neutralizes harmful proteases while allowing the immune system to function normally. This resolves the contradiction by providing graft protection through a different mechanism that avoids the toxic side effects of conventional immunosuppressants.
Solution Approach 2:
The patent changes the therapeutic parameter from immunosuppression to serine protease inhibition. By targeting the biochemical parameter of protease activity rather than immune cell suppression, the treatment achieves graft protection without the toxic side effects associated with traditional immunosuppressive therapy. This parameter change allows for improved efficacy with reduced toxicity.
2Reliability
If conventional immunosuppressive drugs are administered, then graft rejection is reduced, but the need for continuous drug therapy and associated toxicities increase
Solution Approach 1:
The patent enables the graft itself to provide protection by upregulating endogenous alpha-1-antitrypsin production or by administering AAT that protects the graft's own cells. This self-service mechanism reduces dependence on continuous external immunosuppressive drug therapy, as the protective effect is achieved through the graft's own biochemical defenses rather than ongoing suppression of the immune system.
3Reliability
If early intervention with AAT is administered, then GvHD severity is reduced and regulatory T cell recovery is enhanced, but the timing and dosing complexity increases
Solution Approach 1:
The patent administers alpha-1-antitrypsin before or at the time of bone marrow transplantation to prevent GvHD development rather than treating it after onset. This preliminary action simplifies the treatment protocol by preventing the need for complex post-transplantation immunosuppressive regimens and monitoring, while achieving superior efficacy through early protection of the graft.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AAT treatment significantly reduces the incidence and severity of GvHD, enhances regulatory T cell recovery, and prolongs graft survival by altering the donor T effector to T regulatory cell ratio, while minimizing direct effects on donor cells and reducing the need for immunosuppressive drugs.
Implementation Method 1
The enzyme/inhibitor complex is then removed from circulation by binding to serpin-enzyme complex (SEC) receptor and catabolized by the liver and spleen. ATT appears to represent an important part of the defense mechanism against activity by serine proteases.
Data Source
AI summary
Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (α1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT.